Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SPC5001 dose-escalation study in healthy volunteers and familial hypercholesterolemia subjects
NL-OMON36203Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in familial hypercholesterolemia (FH) and hypercholesterolemia comparing SPC5001 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Apr 2011; status: active, not recruiting.
02
Drugs
SPC5001
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON36203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36203.